Real-World Comparative Effectiveness of Nivolumab versus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma

• Published in: Pharmaceutics 2022-10, Vol.14 (11), p.2263
• Main Authors: Kuo, Hsin-Yu, Han, Meng-Zhi, Liao, Chih-Hsiang, Lin, Yih-Jyh, Wang, Chung-Teng, Chen, Shang-Hung, Chang, Ting-Tsung, Chen, Po-Jun, Lin, Sheng-Hsiang, Chen, Chiung-Yu, Chuang, Chiao-Hsiung, Wu, I-Chin, Wu, Juei-Seng, Hong, Tzu-Chun, Hsieh, Ming-Tsung, Lee, Yang-Cheng, Wu, Hung-Tsung, Tsai, Hong-Ming
• Format: Article
• Language: English
• Subjects: Biopsy; Cellular biology; Drug therapy; FDA approval; hepatocellular carcinoma; Hepatoma; immune checkpoint inhibitors; Immunotherapy; Kinases; Liver cancer; Medical prognosis; nivolumab; Patient outcomes; pembrolizumab; programmed cell death protein-1; Regression analysis
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics14112263

Purpose: Immune checkpoint inhibitors are effective therapies for advanced hepatocellular carcinoma (HCC); however, comparisons of the clinical efficacy and safety profile for these drugs are still scarce. Thus, the aims of this study were to investigate the differences in efficacy and safety between nivolumab and pembrolizumab in unresectable HCC patients in a real-world setting. Patients and methods: A total of 115 patients who received treatment with nivolumab (n = 73) or pembrolizumab (n = 42) in combination with or without tyrosine kinase inhibitors was enrolled. Therapeutic response, survival outcomes, and safety profiles were compared among these groups. Multivariate analysis of survival response was performed using Cox proportional hazards regression. Results: Patients treated with pembrolizumab demonstrated a significantly higher objective response rate than those with nivolumab (38.1% vs. 15.1%; odds ratio 4.18, p = 0.005) regardless of the combination strategies. In addition, pembrolizumab performed a better overall survival (OS) than nivolumab, (34.9 vs. 9.5 months; hazard ratio (HR) = 0.39, p = 0.004). In subgroup analysis, pembrolizumab exhibited favorable OS than nivolumab for monotherapy (HR = 0.16, p = 0.001) or combination therapy (HR = 0.33, p = 0.006) as second-line or later-line (HR = 0.19, p = 0.001) therapy and those with (HR = 0.31, p = 0.006) or without (HR = 0.15, p = 0.004) well-compensated liver disease. The incidence of adverse events was comparable for both treatments. Conclusion: Both pembrolizumab and nivolumab had significant effects for HCC therapy, and pembrolizumab had a significant survival benefit as compared with nivolumab.